1-(2-(Piperidin-1-yl)ethyl)-1H-indol-5-amine | 753021-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(2-(Piperidin-1-yl)ethyl)-1H-indol-5-amine
• 英文别名: 5-amino-1-(2-piperidin-1-yl-ethyl)-1H-indole；1-(2-piperidin-1-ylethyl)indol-5-amine
• CAS: 753021-24-8
• 化学式: C₁₅H₂₁N₃
• 分子量: 243.352
• InChiKey: RPMOUTPUYLFILB-UHFFFAOYSA-N

物化性质

• 沸点：
  439.4±25.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-(Piperidin-1-yl)ethyl)-1H-indol-5-amine 在 盐酸 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 反应 0.17h， 生成 N'-[1-(2-piperidin-1-ylethyl)indol-5-yl]thiophene-2-carboximidamide;hydrochloride
  参考文献：
  名称：

  1,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase inhibitors

  摘要：

  A series of 1,5-disubstituted indole derivatives was designed, synthesized and evaluated as inhibitors of human nitric oxide synthase. A variety of flexible and restricted basic amine side chain substitutions was explored at the 1-position of the indole ring, while keeping the amidine group fixed at the 5-position. Compounds having N-(1-(2-(1-methylpyrrolidin-2-yl) ethyl)- (12, (R)-12, (S)-12 and 13) and N-(1-(1-methylazepan-4-yl)-side chains (14, 15, (-)-15 and (+)-15) showed increased inhibitory activity for the human nNOS isoform and selectivity over eNOS and iNOS isoforms. The most potent compound of the series for human nNOS (IC(50) = 0.02 mu M) (S)-12 showed very good selectivity over the eNOS (eNOS/nNOS = 96-fold) and iNOS (iNOS/nNOS = 850-fold) isoforms. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.022
• 作为产物：
  描述：

  5-硝基吲哚 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0~80.0 ℃ 、137.9 kPa 条件下， 生成 1-(2-(Piperidin-1-yl)ethyl)-1H-indol-5-amine
  参考文献：
  名称：

  药物化学驱动着朝向新型和选择性5-羟色胺5-HT6受体配体的方法。

  摘要：

  基于药物化学指导的假设药效团模型，新系列的吲哚基磺酰胺已被设计和制备为选择性和高亲和性5-羟色胺5-HT（6）受体配体。此外，基于发现库的筛选方法，一系列苯并恶嗪哌啶基磺酰胺被鉴定为选择性5-HT（6）配体。本文中描述的许多化合物具有出色的亲和力，显示的pK（i）值大于8（某些甚至大于9），并且对宽范围（> 50）的其他CNS相关受体具有高选择性。首先，讨论了这些配体的结构亲和性关系。就功能而言，制备了高亲和力的拮抗剂，以及激动剂，甚至部分激动剂。化合物19c和19g代表文献中报道的最高亲和力5-HT（6）激动剂。这些有价值的工具化合物应允许详细研究5-HT（6）受体在相关的动物模型疾病中的作用，例如认知缺陷，抑郁，焦虑或肥胖。

  DOI：

  10.1021/jm049615n

文献信息

• Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT₆ Receptor Ligands
  作者：Jörg Holenz、Ramon Mercè、José Luis Díaz、Xavier Guitart、Xavier Codony、Alberto Dordal、Gonzalo Romero、Antoni Torrens、Josep Mas、Blas Andaluz、Susana Hernández、Xavier Monroy、Elisabeth Sánchez、Enrique Hernández、Raquel Pérez、Roger Cubí、Olga Sanfeliu、Helmut Buschmann

  DOI：10.1021/jm049615n

  日期：2005.3.1

  high selectivities against a wide range (>50) of other CNS relevant receptors. First, structure-affinity relationships of these ligands are discussed. In terms of functionality, high-affinity antagonists, as well as agonists and even partial agonists, were prepared. Compounds 19c and 19g represent the highest-affinity 5-HT(6) agonists ever reported in the literature. These valuable tool compounds should

  基于药物化学指导的假设药效团模型，新系列的吲哚基磺酰胺已被设计和制备为选择性和高亲和性5-羟色胺5-HT（6）受体配体。此外，基于发现库的筛选方法，一系列苯并恶嗪哌啶基磺酰胺被鉴定为选择性5-HT（6）配体。本文中描述的许多化合物具有出色的亲和力，显示的pK（i）值大于8（某些甚至大于9），并且对宽范围（> 50）的其他CNS相关受体具有高选择性。首先，讨论了这些配体的结构亲和性关系。就功能而言，制备了高亲和力的拮抗剂，以及激动剂，甚至部分激动剂。化合物19c和19g代表文献中报道的最高亲和力5-HT（6）激动剂。这些有价值的工具化合物应允许详细研究5-HT（6）受体在相关的动物模型疾病中的作用，例如认知缺陷，抑郁，焦虑或肥胖。
• 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity
  申请人：Maddaford Shawn

  公开号：US20070254940A1

  公开（公告）日：2007-11-01

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, or chronic pain.

  本发明涉及一种一氧化氮合酶（NOS）的抑制剂，特别是那些选择性地抑制神经一氧化氮合酶（nNOS）而不是其他NOS同工酶。本发明的NOS抑制剂，单独或与其他药用活性剂联合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥手术（CABG）、有或无先兆的偏头痛、伴有触痛的偏头痛、中枢性中风后疼痛（CPSP）、神经病性疼痛或慢性疼痛等病症。
• Beta-ketoamide compounds with MCH antagonistic activity
  申请人：Roth Juergen Gerald

  公开号：US20050245500A1

  公开（公告）日：2005-11-03

  Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R 1 , R 2 , R 3 , R 5a and R 5b have the meanings given in claim 1 . The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

  式I中的化合物，其中基团和残基A、B、b、X、Y、Z、R1、R2、R3、R5a和R5b的含义如权利要求1所述。本发明还涉及含有根据本发明的至少一种酰胺的药物组合物。由于其MCH受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过食症和糖尿病。
• 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
  申请人：NeurAxon, Inc.

  公开号：US07989447B2

  公开（公告）日：2011-08-02

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, or chronic pain.

  本发明涉及一种一氧化氮合酶（NOS）抑制剂，特别是那些能够选择性地抑制神经型一氧化氮合酶（nNOS）而不影响其他NOS同工酶。本发明的NOS抑制剂可以单独或与其他药物活性剂联合使用，用于治疗或预防中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥术（CABG）、带和不带先兆的偏头痛、带有痛觉过敏的偏头痛、中枢后中风痛（CPSP）、神经性疼痛或慢性疼痛等症状。
• MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Shanghai de Novo Pharmatech Co., Ltd.

  公开号：EP3604306A1

  公开（公告）日：2020-02-05

  A macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one as represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a composition comprising the compound as represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method therefor, use thereof as a Wee1 inhibitor and use thereof as a sensitizer in chemotherapy or a radiotherapy of cancers. The macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and relating signaling pathways, having good therapeutic and relieving effects on cancers.

  一种由式(I)代表的吡唑并[3,4-d]嘧啶-3-酮的大环衍生物和/或其药学上可接受的盐、一种由式(I)代表的化合物和/或其药学上可接受的盐组成的组合物、其制备方法、其作为Wee1抑制剂的用途以及其在癌症化疗或放疗中作为增敏剂的用途。 吡唑并[3,4-d]嘧啶-3-酮的大环衍生物能有效抑制Wee1及相关信号通路，对癌症具有良好的治疗和缓解作用。